Tuesday, September 30, 2008

Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology

THOUSAND OAKS, Calif., – Sep 30, 2008 – Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).

Posted in Press Releases